Astellas' gastric cancer therapy gets UK ... as it looks to expand its drug pipeline and research base in the Boston area. Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics ...
Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...
Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing. Astellas ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback